This Market Spotlight report covers the Erectile Dysfunction market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

• Datamonitor Healthcare estimates that in 2019, there were 401.4 million prevalent cases of erectile dysfunction in males aged 20 years and older worldwide, and forecasts that number to increase to 450.2 million cases by 2028.
• Prevalence proportions for erectile dysfunction range between 14.0% and 22.0% in males aged 20 years and older worldwide. The approved drugs in the erectile dysfunction space target phosphodiesterase 5, prostaglandin E receptor 1, alpha 2 adrenergic receptor, and vasoactive intestinal peptide receptor. The majority of approved drugs in the erectile dysfunction space are administered via the oral route, with the remainder being intracavitary, intraurethral, intravenous, and sublingual/oral transmucosal formulations.
• The largest proportion of industry-sponsored drugs in active clinical development for erectile dysfunction are in Phase I, with only one drug in the NDA/BLA phase.
• Therapies in development for erectile dysfunction focus on targets such as phosphodiesterase 5, potassium channels, voltagegated calcium channels, and stem cells/other cell therapies. The largest proportion of these drugs are administered via the sublingual/oral transmucosal route.
• High-impact upcoming events for drugs in the erectile dysfunction space comprise an expected European approval decision as well as expected CHMP filing results for Wafesil.
• The overall likelihood of approval of a Phase I urology asset is 12.7%, and the average probability a drug advances from Phase III is 77.3%. Drugs, on average, take 9.0 years from Phase I to approval in the overall urology space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for erectile dysfunction have been in the late phases of development, with 67% of trials in Phase III–IV, and 33% in Phase I–II.
• The US leads in terms of the number of erectile dysfunction clinical trials globally. France leads the major European markets, while South Korea has the top spot in Asia.
• Clinical trial activity in the erectile dysfunction space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for erectile dysfunction, with 24 trials.
• Pfizer leads industry